Loading...
RDNA-07. IDH1-MUTANT GLIOBLASTOMA (GBM) CELLS FROM A PATIENT POST-TUMOR TREATING FIELDS (TTFIELDS) THERAPY ARE SENSITIVE TO TTFIELDS IN VITRO
BACKGROUND: Tumor treating fields (TTFields) are FDA-approved for treatment of newly-diagnosed and recurrent GBM. TTFields extend progression-free survival and overall survival. Despite this advancement in patient outcome, many patients undergoing TTFields treatment ultimately progress with tumor re...
Na minha lista:
| Udgivet i: | Neuro Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217513/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.923 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|